Monday, December 16, 2019
LG Chem Promotes Excellence of Zemiglo in European Diabetes Study Meeting
Presentation in Prestigious Meeting
LG Chem Promotes Excellence of Zemiglo in European Diabetes Study Meeting
  • By Jung Min-hee
  • September 15, 2017, 02:30
Share articles

LG Chem announced the results of its research on Zemiglo in an annual meeting of the European Association for Study of Diabetes held in Lisbon, Portugal on September 14. (photo courtesy: LG Chem)
LG Chem announced the results of its research on Zemiglo in an annual meeting of the European Association for Study of Diabetes held in Lisbon, Portugal on September 14. (photo courtesy: LG Chem)

 

An image of LG Chem’s Zemiglo. (photo courtesy: LG Chem)
An image of LG Chem’s Zemiglo. (photo courtesy: LG Chem)

 

LG Chem announced on September 14 that the company made a presentation on the results of a study on the excellent efficacy and safety of Zemiglo in an annual meeting of the European Association for Study of Diabetes with the world's most prestigious authority in Lisbon, Portugal.

The European Association for Study of Diabetes is the most prestigious society in the field of diabetes and about 20,000 people from the medical sector and global pharmaceutical companies participate in the event to exchanges various information on treating diabetes.

LG Chem held a symposium entitled "Solution for Early to Type 2 Diabetes Patients" in this meeting and received good responses from audiences by informing of the excellence of Zemiglo based on rich clinical trial data.

LG Chem began the sale of Zemiglo in Korea in 2012. Since 2013, LG Chem is accelerating its global market penetration through sales contracts with global pharmaceutical companies Sanofi and Stendhal. LG Chem has obtained permission to sell Zemiglo in India, Thailand, and South American countries and is planning to steadily expand export markets.